Use of real-world evidence to support regulatory decisions on medical devices in China and a unique opportunity to gain accelerated approval in “Boao Lecheng Pilot Zone”

[1]  M. Yao,et al.  [Real-world data studies of medical products in the context of special healthcare policy: study designs and key considerations]. , 2021, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[2]  Zhong Wang.  Data integration of electronic medical record under administrative decentralization of medical insurance and healthcare in China: a case study , 2019, Israel Journal of Health Policy Research.

[3]  L. Tang,et al.  Real world evidence: experience and lessons from China , 2018, British Medical Journal.

[4]  Luxia Zhang,et al.  Big data and medical research in China , 2018, British Medical Journal.

[5]  B. Bengtsson,et al.  Lifetime risk of blindness in open-angle glaucoma. , 2013, American journal of ophthalmology.

[6]  H. Quigley,et al.  The number of people with glaucoma worldwide in 2010 and 2020 , 2006, British Journal of Ophthalmology.

[7]  H. Quigley.  Number of people with glaucoma worldwide. , 1996, The British journal of ophthalmology.

[8]  M. Morales i Ballús,et al.  The number of people with glaucoma worldwide in 2010 and 2020 , 2006 .

[9]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[10]  L. Katz,et al.  Medical devices. , 1985, Dimensions in health service.